ScholarIQanswers from OpenAlex & ORCID
S. Vincent Rajkumar
ResearcherPublications, citations & collaboration network
S. Vincent Rajkumar is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does S. Vincent Rajkumar have?
ScholarIQindexed works
S. Vincent Rajkumar has 1,857 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does S. Vincent Rajkumar have?
ScholarIQcitation count
S. Vincent Rajkumar has 132,342 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of S. Vincent Rajkumar?
ScholarIQh-index
S. Vincent Rajkumar has an h-index of 166 in OpenAlex.
What is the i10-index of S. Vincent Rajkumar?
ScholarIQi10-index
S. Vincent Rajkumar has an i10-index of 847 in OpenAlex.
What is the ORCID of S. Vincent Rajkumar?
ScholarIQorcid
The ORCID for S. Vincent Rajkumar is on the source record.
What is the OpenAlex record for S. Vincent Rajkumar?
ScholarIQopenalex
The OpenAlex for S. Vincent Rajkumar is on the source record.
What are the most-cited papers on S. Vincent Rajkumar?
ScholarIQmost cited works
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C. Anderson, Brian G.M. Durie, Ola Landgren, Philippe Moreau, Nikhil C. Munshi, Sagar Lonial, Joan Bladé, María‐Victoria Mateos, Meletios Α. Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Z. Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z. Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans Erik Johnsen, Evangelos Terpos, Tony Reiman, Robert A. Kyle, Pieter Sonneveld, Paul G. Richardson, Philip L. McCarthy, Heinz Ludwig, Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Nelson Leung, Frank Bridoux, Vecihi Batuman, Aristeidis Chaidos, Paul Cockwell, Vivette D. D’Agati, Angela Dispenzieri, Fernando C. Fervenza, Jean-Paul Fermand, Simon Gibbs, Julian D. Gillmore, Guillermo A. Herrera, Arnaud Jaccard, Dragan Jevremović, Efstathios Kastritis, Vishal Kukreti, Robert A. Kyle, Helen J. Lachmann, Christopher P. Larsen, Heinz Ludwig, Glen S. Markowitz, Giampaolo Merlini, Peter Mollee, Maria M. Picken, S. Vincent Rajkumar, Virginie Royal, Paul W. Sanders, Sanjeev Sethi, Christopher P. Venner, Peter M. Voorhees, Ashutosh Wechalekar, Brendan M. Weiss, Samih H. Nasr
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson, Emily Blood, Constantine S. Mitsiades, Sundar Jagannath, Steven R. Zeldenrust, Melissa Alsina, Robert Schlossman, S. Vincent Rajkumar, K.R. Desikan, Teru Hideshima, Nikhil C. Munshi, Kathleen Kelly-Colson, Deborah Doss, Mary McKenney, Svetlana G. Gorelik, Diane Warren, Andrea Freeman, Rebecca L. Rich, Anfang Wu, Marta Olesnyckyj, Kenton Wride, William S. Dalton, Jerome B. Zeldis, Robert Knight, Edie Weller, Kenneth C. Anderson
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji Kumar, Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina K. Singh, Terri L. Parker, Alexander Menter, Xuezhong Yang, Benjamin M. Parsons, Pankaj Kumar, Prashant Kapoor, Aaron S. Rosenberg, Jeffrey A. Zonder, Edward A. Faber, Sagar Lonial, Kenneth C. Anderson, Paul G. Richardson, Robert Z. Orlowski, Lynne I. Wagner, S. Vincent Rajkumar